Marta Valenza1, Luca Steardo, Pietro Cottone, Valentina Sabino. 1. Laboratory of Addictive Disorders, Departments of Pharmacology and Psychiatry, Boston University School of Medicine, 72 E Concord St, R-612 or R-618, Boston, MA, 02118, USA.
Abstract
RATIONALE: Obesity is a leading public health problem worldwide. Multiple lines of evidence associate deficits in the brain reward circuit with obesity. OBJECTIVE: Whether alterations in brain reward sensitivity precede or are a consequence of obesity is unknown. This study aimed to investigate both innate and obesity-induced differences in the sensitivity to the effects of an indirect dopaminergic agonist. METHODS: Rats genetically prone to diet-induced obesity (DIO) and their counterpart diet-resistant (DR) were fed a chow diet, and their response to D-amphetamine on intracranial self-stimulation and food intake were assessed. The same variables were then evaluated after exposing the rats to a high-fat diet, after DIO rats selectively developed obesity. Finally, gene expression levels of dopamine receptors 1 and 2 as well as tyrosine hydroxylase were measured in reward-related brain regions. RESULTS: In a pre-obesity state, DIO rats showed innate decreased sensitivity to the reward-enhancing and anorectic effects of D-amphetamine, as compared to DR rats. In a diet-induced obese state, the insensitivity to the potentiating effects of D-amphetamine on intracranial self-stimulation (ICSS) threshold persisted and became more marked in DIO rats, while the anorectic effects were comparable between genotypes. Finally, innate and obesity-induced differences in the gene expression of dopamine receptors were observed. CONCLUSIONS: Our results demonstrate that brain reward deficits antedate the development of obesity and worsen after obesity is fully developed, suggesting that these alterations represent vulnerability factors for its development. Moreover, our data suggests that the reward-enhancing and anorectic effects of D-amphetamine are dissociable in the context of obesity.
RATIONALE: Obesity is a leading public health problem worldwide. Multiple lines of evidence associate deficits in the brain reward circuit with obesity. OBJECTIVE: Whether alterations in brain reward sensitivity precede or are a consequence of obesity is unknown. This study aimed to investigate both innate and obesity-induced differences in the sensitivity to the effects of an indirect dopaminergic agonist. METHODS:Rats genetically prone to diet-induced obesity (DIO) and their counterpart diet-resistant (DR) were fed a chow diet, and their response to D-amphetamine on intracranial self-stimulation and food intake were assessed. The same variables were then evaluated after exposing the rats to a high-fat diet, after DIOrats selectively developed obesity. Finally, gene expression levels of dopamine receptors 1 and 2 as well as tyrosine hydroxylase were measured in reward-related brain regions. RESULTS: In a pre-obesity state, DIOrats showed innate decreased sensitivity to the reward-enhancing and anorectic effects of D-amphetamine, as compared to DR rats. In a diet-induced obese state, the insensitivity to the potentiating effects of D-amphetamine on intracranial self-stimulation (ICSS) threshold persisted and became more marked in DIOrats, while the anorectic effects were comparable between genotypes. Finally, innate and obesity-induced differences in the gene expression of dopamine receptors were observed. CONCLUSIONS: Our results demonstrate that brain reward deficits antedate the development of obesity and worsen after obesity is fully developed, suggesting that these alterations represent vulnerability factors for its development. Moreover, our data suggests that the reward-enhancing and anorectic effects of D-amphetamine are dissociable in the context of obesity.
Authors: Annette E Fleckenstein; Trent J Volz; Evan L Riddle; James W Gibb; Glen R Hanson Journal: Annu Rev Pharmacol Toxicol Date: 2007 Impact factor: 13.820
Authors: Jon F Davis; Andrea L Tracy; Jennifer D Schurdak; Matthias H Tschöp; Jack W Lipton; Deborah J Clegg; Stephen C Benoit Journal: Behav Neurosci Date: 2008-12 Impact factor: 1.912
Authors: Clara Velázquez-Sánchez; Antonio Ferragud; Catherine F Moore; Barry J Everitt; Valentina Sabino; Pietro Cottone Journal: Neuropsychopharmacology Date: 2014-04-29 Impact factor: 7.853
Authors: Elizabeth E Steinberg; Josiah R Boivin; Benjamin T Saunders; Ilana B Witten; Karl Deisseroth; Patricia H Janak Journal: PLoS One Date: 2014-04-14 Impact factor: 3.240
Authors: Catherine F Moore; Julia I Panciera; Valentina Sabino; Pietro Cottone Journal: Philos Trans R Soc Lond B Biol Sci Date: 2018-03-19 Impact factor: 6.237
Authors: Edward C Gaiser; Jean-Dominique Gallezot; Patrick D Worhunsky; Ania M Jastreboff; Brian Pittman; Lauren Kantrovitz; Gustavo A Angarita; Kelly P Cosgrove; Marc N Potenza; Robert T Malison; Richard E Carson; David Matuskey Journal: Neuropsychopharmacology Date: 2016-07-04 Impact factor: 7.853